To receive daily emails from Breaking Christian News to your inbox CLICK HERE
"Life-Changing Day" for Migraine Sufferers as FDA Approves First-Ever Drug to Prevent Chronic HeadachesIt's a once-a-month injection, effective for people who suffer from migraines at least four days a month. (Washington, DC)—[FDA.gov] The U.S. Food and Drug Administration today approved Aimovig for the preventive treatment of migraine in adults. The treatment is given by once-monthly self-injections. Aimovig is the first FDA-approved preventive migraine treatment in a new class of drugs that work by blocking the activity of calcitonin gene-related peptide, a molecule that is involved in migraine attacks. (Image credit: Miss Rogue-Flickr) "Aimovig provides patients with a novel option for reducing the number of days with migraine," said Eric Bastings, M.D., deputy director of the Division of Neurology Products in the FDA's Center for Drug Evaluation and Research. "We need new treatments for this painful and often debilitating condition." Patients often describe migraine headache pain as an intense pulsing or throbbing pain in one area of the head. Additional symptoms include nausea and/or vomiting and sensitivity to light and sound. Approximately one-third of affected individuals can predict the onset of a migraine because it is preceded by an aura—transient sensory or visual disturbances that appear as flashing lights, zig-zag lines or a temporary loss of vision. People with migraine tend to have recurring attacks triggered by a number of different factors, including stress, hormonal changes, bright or flashing lights, lack of food or sleep and diet. Migraine is three times more common in women than in men and affects more than 10 percent of people worldwide. The effectiveness of Aimovig for the preventive treatment of migraine was evaluated in three clinical trials. The first study included 955 participants with a history of episodic migraine and compared Aimovig to placebo. Over the course of six months, Aimovig-treated patients experienced, on average, one to two fewer monthly migraine days than those on placebo. The second study included 577 patients with a history of episodic migraine and compared Aimovig to placeb. The most common side effects that patients in the clinical trials reported were injection site reactions and constipation. The FDA granted the approval of Aimovig to Amgen Inc.
To receive daily emails from Breaking Christian News to your inbox CLICK HERE Other Recent Articles from Breaking Christian News Trump Under Fire for Endorsing the Bible, Urging Americans to Pray Speaker Johnson Announces He'll Invite Netanyahu to Address Congress Federal Appeals Court Rules Pennsylvania Must Only Count Mail Ballots With Dates, Signatures President Trump to Join Wake Honoring Slain NYPD Officer, While Biden Attends Fundraiser Elon Musk to Pay Embattled Doctor's Legal Fees after Speaking Out against COVID Lockdowns Safety of Women Hangs in Balance after Oral Arguments on Abortion Pill Regulation New Federal Gun Grab Law Would Criminalize Shooting Ranges, and Even Private Security Treasury Sec. Yellen: Biden Has NO Plan to Save Social Security Chick-fil-A Abandons Long-Held 'No Antibiotics' Pledge on Chicken The War in Myanmar: Karenni Resistance Fighters Ask for Prayer and Practical Help The World Is Facing a Major Population Crisis by 2075 If Birth Rates Keep Falling FDA Admits COVID Vaccines Cause Seizures in Toddlers Kamala Harris Won't Disclose Why Biden Campaign Is Active on TikTok Despite Security Worries Search the Articles Archives |
All articles on this site and emails from BCN are copyrighted property of Breaking Christian News. Permission is given to link to, or share a BCN story if proper attribution is given to both the original writer and summarizer of the story. Breaking Christian News 2005-2019. All Rights Reserved.
Breaking Christian News is a division of Elijah List Publications, Inc. All Rights Reserved
Disclaimer: Articles and links, as well as the source articles linked to; do not necessarily reflect the opinion of Breaking Christian News.
Home | Store | Subscribe | Facebook | Article Archive |